R&D

17. Hua Medicine announced on July 1 the core data of the 24-week results of the phase III registered clinical study (HMM0302) of its global first-in-class glucokinase activator (GKA) dorzagliatin (HMS5552) in combination with metformin. According to the data, dorzagliatin demonstrated fast onset, potent and sustained HbA1c reduction of subjects’ blood glucose level of 1.02% from baseline at 24-week, significantly superior to a reduction of 0.36% (least squares mean) from baseline for the placebo group (p-value<0.0001).

18. On July 1, Junshi registered a prospective, randomized, controlled, double-blind, multicenter phase III clinical study of toripalimab in combination with lenvatinib vs lenvatinib as a first-line therapy for advanced HCC.

19. Hengrui announced on July 2 that its Class 1 new drug SHR0302 base ointment was approved for a clinical trial to treat vitiligo. According to the announcement, the accumulative R&D expenses for SHR0302 project have reached about RMB173 million. As a selective small molecule JAK1 inhibitor, SHR0302 base is planned to treat vitiligo.

Related reading:

Pharmaceutical News of the Week (June. 29th-July. 3rd) | PharmaSources.com Approvals - Updates on Approvals

About  the Author:    

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.